ABL1 and lung adenocarcinoma: Data from The Cancer Genome Atlas (TCGA) showed alterations of ABL1 and ABL2 in human lung adenocarcinomas, including copy number enhancement of ABL2 and somatic mutations in ABL1 in 1-2% of patients [2].